ArticleHuman vaccines & immunotherapeutics2026
Antibody levels and immune memory in children with kaposiform hemangioendothelioma treated with sirolimus after catch up vaccination.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the safety, immunogenicity, and post-vaccination immune responses of timely, sequential catch-up vaccination in children with Kaposiform hemangioendothelioma (KHE) undergoing sirolimus treatment. From July 2020 to November 2021, sixteen children with KHE receiving sirolimus in sustained remission were enrolled, along with 15 age-matched healthy children as controls. Patients in the sirolimus-treated group underwent immune assessment prior to receiving catch-up vaccinations, including Hepatitis B, Measles-Mumps-Rubella (MMR), Epidemic Encephalitis B, and meningococcal vaccines. Demographic characteristics, clinical outcomes, immune cell profiles, viral antibody indices, and post-vaccination adverse events were systematically recorded. Vaccination was well tolerated in sirolimus-treated children, with only one case of transient low-grade fever and tonsillitis reported. Seroprotective antibody responses to both live-attenuated and inactivated vaccines were comparable between the sirolimus-treated group and healthy controls. Notably, the proportion of IgG
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.